US 11,699,503 B2
Methods of identifying and treating patient populations amenable to cancer immunotherapy
Matthew Spitzer, San Francisco, CA (US); and Lawrence Fong, San Francisco, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Appl. No. 16/479,211
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Jan. 19, 2018, PCT No. PCT/US2018/014503
§ 371(c)(1), (2) Date Jul. 18, 2019,
PCT Pub. No. WO2018/136784, PCT Pub. Date Jul. 26, 2018.
Claims priority of provisional application 62/448,281, filed on Jan. 19, 2017.
Prior Publication US 2019/0378594 A1, Dec. 12, 2019
Int. Cl. G16B 25/10 (2019.01); G16B 5/10 (2019.01); G16B 45/00 (2019.01); A61K 38/19 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); G01N 33/50 (2006.01)
CPC G16B 25/10 (2019.02) [A61K 38/193 (2013.01); A61K 39/3955 (2013.01); C07K 16/2818 (2013.01); G01N 33/505 (2013.01); G16B 5/10 (2019.02); G16B 45/00 (2019.02); G01N 2333/70596 (2013.01)] 14 Claims
 
1. A method of treating cancer in a human subject having cancer comprising:
(a) generating a first scaffold map from a first population of blood leukocytes isolated from the human subject having cancer, wherein the cancer is melanoma, and a second scaffold map from a second population of blood leukocytes isolated from a control, wherein the control is the human subject having cancer at an earlier time, a distinct human subject having cancer that is unresponsive to anti-cancer immunotherapy, or a healthy human subject, wherein the cancer is melanoma;
(b) generating a first cell population expression profile from the first scaffold map, and a second cell population expression profile from the second scaffold map;
(c) comparing the first cell population expression profile and the second cell population expression profile to determine expression level of CD127low PD-1low T cells in the human subject having cancer and the control;
(d) administering a therapeutically effective amount of a composition comprising an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is ipilumimab, to the human subject having cancer, if the expression level of CD127low PD-1low T cells in the human subject having cancer is greater than the expression level of CD127low PD-1low T cells in the control, thereby treating the cancer in the human subject having cancer.